- Home
- Publications
- Publication Search
- Publication Details
Title
Overview of Research into mTOR Inhibitors
Authors
Keywords
-
Journal
MOLECULES
Volume 27, Issue 16, Pages 5295
Publisher
MDPI AG
Online
2022-08-22
DOI
10.3390/molecules27165295
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Design, synthesis and biological evaluation of dual mTOR/HDAC6 inhibitors in MDA-MB-231 cells
- (2021) Dahong Yao et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- Identification and optimization of 3-bromo-N’-(4-hydroxybenzylidene)-4-methylbenzohydrazide derivatives as mTOR inhibitors that induce autophagic cell death and apoptosis in triple-negative breast cancer
- (2021) Tian Xu et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- In Silico and In Cell Hybrid Selection of Nonrapalog Ligands to Allosterically Inhibit the Kinase Activity of mTORC1
- (2021) Raef Shams et al. JOURNAL OF MEDICINAL CHEMISTRY
- Discovery of novel pyrazolopyrimidine derivatives as potent mTOR/HDAC bi-functional inhibitors via pharmacophore-merging strategy
- (2021) Mingming Zhang et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- Design, synthesis and biological evaluation of novel hybrids targeting mTOR and HDACs for potential treatment of hepatocellular carcinoma
- (2021) Shiyang Zhai et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Discovery of a Brain-Penetrant ATP-Competitive Inhibitor of the Mechanistic Target of Rapamycin (mTOR) for CNS Disorders
- (2020) Simone Bonazzi et al. JOURNAL OF MEDICINAL CHEMISTRY
- Characterization of SPK 98, a Torin2 analog, as ATR and mTOR dual kinase inhibitor
- (2020) Rashmi Bhakuni et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- Discovery of a Novel Dual Histone Deacetylases (HDACs) and Mammalian Target of Rapamycin (mTOR) Target Inhibitor as a Promising Strategy for Cancer Therapy
- (2019) Yong Chen et al. JOURNAL OF MEDICINAL CHEMISTRY
- Discovery of 3-Oxabicyclo[4.1.0]heptane, a Non-nitrogen Containing Morpholine Isostere, and Its Application in Novel Inhibitors of the PI3K-AKT-mTOR Pathway
- (2019) Heather Hobbs et al. JOURNAL OF MEDICINAL CHEMISTRY
- Anticancer compound XL765 as PI3K/mTOR dual inhibitor: A structural insight into the inhibitory mechanism using computational approaches
- (2019) Mohd Rehan PLoS One
- Rational discovery of a highly novel and selective mTOR inhibitor
- (2019) Stanley Jin et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- Design, synthesis and pharmacological evaluation of a novel mTOR-targeted anti-EV71 agent
- (2019) Tianlong Hao et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- A Conformational Restriction Strategy for the Identification of a Highly Selective Pyrimido-pyrrolo-oxazine mTOR Inhibitor
- (2019) Chiara Borsari et al. JOURNAL OF MEDICINAL CHEMISTRY
- Highly Selective, Potent, and Oral mTOR Inhibitor for Treatment of Cancer as Autophagy Inducer
- (2018) Qingxiang Guo et al. JOURNAL OF MEDICINAL CHEMISTRY
- Voxtalisib (XL765) in patients with relapsed or refractory non-Hodgkin lymphoma or chronic lymphocytic leukaemia: an open-label, phase 2 trial
- (2018) Jennifer R Brown et al. Lancet Haematology
- Discovery and Preclinical Characterization of 5-[4,6-Bis({3-oxa-8-azabicyclo[3.2.1]octan-8-yl})-1,3,5-triazin-2-yl]-4-(difluoromethyl)pyridin-2-amine (PQR620), a Highly Potent and Selective mTORC1/2 Inhibitor for Cancer and Neurological Disorders
- (2018) Denise Rageot et al. JOURNAL OF MEDICINAL CHEMISTRY
- Design, synthesis, and biological evaluation of imidazo[1,2- b ]pyridazine derivatives as mTOR inhibitors
- (2017) Beibei Mao et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- 5-(4,6-Dimorpholino-1,3,5-triazin-2-yl)-4-(trifluoromethyl)pyridin-2-amine (PQR309), a Potent, Brain-Penetrant, Orally Bioavailable, Pan-Class I PI3K/mTOR Inhibitor as Clinical Candidate in Oncology
- (2017) Florent Beaufils et al. JOURNAL OF MEDICINAL CHEMISTRY
- 4-Nonylphenol induces autophagy and attenuates mTOR-p70S6K/4EBP1 signaling by modulating AMPK activation in Sertoli cells
- (2017) Peng Duan et al. TOXICOLOGY LETTERS
- mTORC1 signalling and eIF4E/4E-BP1 translation initiation factor stoichiometry influence recombinant protein productivity from GS-CHOK1 cells
- (2016) L. Josse et al. BIOCHEMICAL JOURNAL
- PI3K/Akt/mTOR Signaling and Plasma Membrane Proteins Are Implicated in Responsiveness to Adjuvant Dendritic Cell Vaccination for Metastatic Colorectal Cancer
- (2016) David C. Qian et al. CLINICAL CANCER RESEARCH
- Targeting PI3K/mTOR signaling exerts potent antitumor activity in pheochromocytomain vivo
- (2016) Misu Lee et al. ENDOCRINE-RELATED CANCER
- Induction of autophagy by salidroside through the AMPK-mTOR pathway protects vascular endothelial cells from oxidative stress-induced apoptosis
- (2016) Xiang-Tao Zheng et al. MOLECULAR AND CELLULAR BIOCHEMISTRY
- Akt/AMPK/mTOR pathway was involved in the autophagy induced by vitamin E succinate in human gastric cancer SGC-7901 cells
- (2016) Yang Yu et al. MOLECULAR AND CELLULAR BIOCHEMISTRY
- Overcoming mTOR resistance mutations with a new-generation mTOR inhibitor
- (2016) Vanessa S. Rodrik-Outmezguine et al. NATURE
- Inhibition of mTOR's Catalytic Site by PKI-587 Is a Promising Therapeutic Option for Gastroenteropancreatic Neuroendocrine Tumor Disease
- (2016) Helma Freitag et al. NEUROENDOCRINOLOGY
- CZ415, a Highly Selective mTOR Inhibitor Showing in Vivo Efficacy in a Collagen Induced Arthritis Model
- (2016) Andrew D. Cansfield et al. ACS Medicinal Chemistry Letters
- PI3K/Akt/mTOR signaling pathway and targeted therapy for glioblastoma
- (2016) Xiaoman Li et al. Oncotarget
- 4-(N-Phenyl-N′-substituted benzenesulfonyl)-6-(4-hydroxyphenyl)quinolines as inhibitors of mammalian target of rapamycin
- (2015) Vunnam Venkateswarlu et al. BIOORGANIC & MEDICINAL CHEMISTRY
- Discovery of novel quinoline-based mTOR inhibitors via introducing intra-molecular hydrogen bonding scaffold (iMHBS): The design, synthesis and biological evaluation
- (2015) Xiaodong Ma et al. BIOORGANIC & MEDICINAL CHEMISTRY
- The role for autophagy in cancer
- (2015) Eileen White JOURNAL OF CLINICAL INVESTIGATION
- mTOR: a pharmacologic target for autophagy regulation
- (2015) Young Chul Kim et al. JOURNAL OF CLINICAL INVESTIGATION
- Optimization of a Series of Triazole Containing Mammalian Target of Rapamycin (mTOR) Kinase Inhibitors and the Discovery of CC-115
- (2015) Deborah S. Mortensen et al. JOURNAL OF MEDICINAL CHEMISTRY
- Discovery of Mammalian Target of Rapamycin (mTOR) Kinase Inhibitor CC-223
- (2015) Deborah S. Mortensen et al. JOURNAL OF MEDICINAL CHEMISTRY
- Discovery of AZD3147: A Potent, Selective Dual Inhibitor of mTORC1 and mTORC2
- (2015) Kurt G. Pike et al. JOURNAL OF MEDICINAL CHEMISTRY
- A Novel Covalent mTOR Inhibitor, DHM25, Shows in Vivo Antitumor Activity against Triple-Negative Breast Cancer Cells
- (2015) Amélie Fouqué et al. JOURNAL OF MEDICINAL CHEMISTRY
- mTOR inhibition activates overall protein degradation by the ubiquitin proteasome system as well as by autophagy
- (2015) Jinghui Zhao et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Lysosomal amino acid transporter SLC38A9 signals arginine sufficiency to mTORC1
- (2015) S. Wang et al. SCIENCE
- Differential regulation of mTORC1 by leucine and glutamine
- (2015) J. L. Jewell et al. SCIENCE
- Current treatment strategies for inhibiting mTOR in cancer
- (2015) Francesca Chiarini et al. TRENDS IN PHARMACOLOGICAL SCIENCES
- mTOR signaling in tumorigenesis
- (2014) Kai Xu et al. BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER
- Design, synthesis, anticancer activity and docking studies of novel 4-morpholino-7,8-dihydro-5H-thiopyrano[4,3-d]pyrimidine derivatives as mTOR inhibitors
- (2014) Wufu Zhu et al. BIOORGANIC & MEDICINAL CHEMISTRY
- Synthesis of 5-substituted-1H-pyrazolo[4,3-d]pyrimidin-7(6H)-one analogs and their biological evaluation as anticancer agents: mTOR inhibitors
- (2014) G. Lakshma Reddy et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Oestradiol signalling through the Akt–mTORC1–S6K1
- (2013) O. Varea et al. BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH
- Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase
- (2013) Deborah S. Mortensen et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- A hit to lead discovery of novel N-methylated imidazolo-, pyrrolo-, and pyrazolo-pyrimidines as potent and selective mTOR inhibitors
- (2013) Wendy Lee et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- Optimization of potent and selective dual mTORC1 and mTORC2 inhibitors: The discovery of AZD8055 and AZD2014
- (2013) Kurt G. Pike et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- The ATP-Competitive mTOR Inhibitor INK128 Enhances In Vitro and In Vivo Radiosensitivity of Pancreatic Carcinoma Cells
- (2013) T. J. Hayman et al. CLINICAL CANCER RESEARCH
- Furthering the design and the discovery of small molecule ATP-competitive mTOR inhibitors as an effective cancer treatment
- (2013) Xiaoqing Lv et al. Expert Opinion on Drug Discovery
- Discovery of a Novel Class of Highly Potent, Selective, ATP-Competitive, and Orally Bioavailable Inhibitors of the Mammalian Target of Rapamycin (mTOR)
- (2013) Craig S. Takeuchi et al. JOURNAL OF MEDICINAL CHEMISTRY
- Pyrimidoaminotropanes as Potent, Selective, and Efficacious Small Molecule Kinase Inhibitors of the Mammalian Target of Rapamycin (mTOR)
- (2013) Anthony A. Estrada et al. JOURNAL OF MEDICINAL CHEMISTRY
- Equivalent Benefit of Rapamycin and a Potent mTOR ATP-Competitive Inhibitor, MLN0128 (INK128), in a Mouse Model of Tuberous Sclerosis
- (2013) Yanan Guo et al. MOLECULAR CANCER RESEARCH
- mTOR kinase structure, mechanism and regulation
- (2013) Haijuan Yang et al. NATURE
- Amino acid signalling upstream of mTOR
- (2013) Jenna L. Jewell et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- Ridaforolimus in advanced or metastatic soft tissue and bone sarcomas
- (2013) Monica M Mita et al. Expert Review of Clinical Pharmacology
- Discovery and optimization of potent and selective imidazopyridine and imidazopyridazine mTOR inhibitors
- (2012) Emily A. Peterson et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- Conformationally-restricted cyclic sulfones as potent and selective mTOR kinase inhibitors
- (2012) Kevin K.-C. Liu et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- Sulfonyl-morpholino-pyrimidines: SAR and development of a novel class of selective mTOR kinase inhibitor
- (2012) M. Raymond V. Finlay et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- Enhanced Apoptosis and Tumor Growth Suppression Elicited by Combination of MEK (Selumetinib) and mTOR Kinase Inhibitors (AZD8055)
- (2012) S. V. Holt et al. CANCER RESEARCH
- mTOR Signaling in Growth Control and Disease
- (2012) Mathieu Laplante et al. CELL
- Potent, Selective, and Orally Bioavailable Inhibitors of the Mammalian Target of Rapamycin Kinase Domain Exhibiting Single Agent Antiproliferative Activity
- (2012) Michael F. T. Koehler et al. JOURNAL OF MEDICINAL CHEMISTRY
- Efficacy of the investigational mTOR kinase inhibitor MLN0128/INK128 in models of B-cell acute lymphoblastic leukemia
- (2012) M R Janes et al. LEUKEMIA
- Discovery and Biological Profiling of Potent and Selective mTOR Inhibitor GDC-0349
- (2012) Zhonghua Pei et al. ACS Medicinal Chemistry Letters
- S6K1 Alternative Splicing Modulates Its Oncogenic Activity and Regulates mTORC1
- (2012) Vered Ben-Hur et al. Cell Reports
- Roles of histone deacetylases in epigenetic regulation: emerging paradigms from studies with inhibitors
- (2012) Geneviève P Delcuve et al. Clinical Epigenetics
- Protor-1 is required for efficient mTORC2-mediated activation of SGK1 in the kidney
- (2011) Laura R. Pearce et al. BIOCHEMICAL JOURNAL
- Benefits of mTOR kinase targeting in oncology: pre-clinical evidence with AZD8055: Figure 1
- (2011) Gayle Marshall et al. BIOCHEMICAL SOCIETY TRANSACTIONS
- Imidazo[1,5-a]pyrazines: Orally efficacious inhibitors of mTORC1 and mTORC2
- (2011) Andrew P. Crew et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- Inhibition of mTOR Kinase by AZD8055 Can Antagonize Chemotherapy-induced Cell Death through Autophagy Induction and Down-regulation of p62/Sequestosome 1
- (2011) Shengbing Huang et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Next-generation mTOR inhibitors in clinical oncology: how pathway complexity informs therapeutic strategy
- (2011) Seth A. Wander et al. JOURNAL OF CLINICAL INVESTIGATION
- Potent, Selective, and Orally Bioavailable Inhibitors of Mammalian Target of Rapamycin (mTOR) Kinase Based on a Quaternary Substituted Dihydrofuropyrimidine
- (2011) Frederick Cohen et al. JOURNAL OF MEDICINAL CHEMISTRY
- Discovery of 9-(6-Aminopyridin-3-yl)-1-(3-(trifluoromethyl)phenyl)benzo[h][1,6]naphthyridin-2(1H)-one (Torin2) as a Potent, Selective, and Orally Available Mammalian Target of Rapamycin (mTOR) Inhibitor for Treatment of Cancer
- (2011) Qingsong Liu et al. JOURNAL OF MEDICINAL CHEMISTRY
- Discovery of a Potent, Selective, and Orally Available Class I Phosphatidylinositol 3-Kinase (PI3K)/Mammalian Target of Rapamycin (mTOR) Kinase Inhibitor (GDC-0980) for the Treatment of Cancer
- (2011) Daniel P. Sutherlin et al. JOURNAL OF MEDICINAL CHEMISTRY
- Discovery and Assembly-Line Biosynthesis of the Lymphostin Pyrroloquinoline Alkaloid Family of mTOR Inhibitors in Salinispora Bacteria
- (2011) Akimasa Miyanaga et al. JOURNAL OF THE AMERICAN CHEMICAL SOCIETY
- Preclinical Characterization of OSI-027, a Potent and Selective Inhibitor of mTORC1 and mTORC2: Distinct from Rapamycin
- (2011) S. V. Bhagwat et al. MOLECULAR CANCER THERAPEUTICS
- Everolimus in Postmenopausal Hormone-Receptor–Positive Advanced Breast Cancer
- (2011) José Baselga et al. NEW ENGLAND JOURNAL OF MEDICINE
- MTORC1 regulates cardiac function and myocyte survival through 4E-BP1 inhibition in mice
- (2010) Denghong Zhang et al. JOURNAL OF CLINICAL INVESTIGATION
- Discovery of 1-(4-(4-Propionylpiperazin-1-yl)-3-(trifluoromethyl)phenyl)-9-(quinolin-3-yl)benzo[h][1,6]naphthyridin-2(1H)-one as a Highly Potent, Selective Mammalian Target of Rapamycin (mTOR) Inhibitor for the Treatment of Cancer
- (2010) Qingsong Liu et al. JOURNAL OF MEDICINAL CHEMISTRY
- Bis(morpholino-1,3,5-triazine) Derivatives: Potent Adenosine 5′-Triphosphate Competitive Phosphatidylinositol-3-kinase/Mammalian Target of Rapamycin Inhibitors: Discovery of Compound26(PKI-587), a Highly Efficacious Dual Inhibitor
- (2010) Aranapakam M. Venkatesan et al. JOURNAL OF MEDICINAL CHEMISTRY
- Discovery of GSK2126458, a Highly Potent Inhibitor of PI3K and the Mammalian Target of Rapamycin
- (2010) Steven D. Knight et al. ACS Medicinal Chemistry Letters
- The discovery and optimisation of pyrido[2,3-d]pyrimidine-2,4-diamines as potent and selective inhibitors of mTOR kinase
- (2009) Karine Malagu et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- Biochemical, Cellular, and In vivo Activity of Novel ATP-Competitive and Selective Inhibitors of the Mammalian Target of Rapamycin
- (2009) K. Yu et al. CANCER RESEARCH
- DEPTOR Is an mTOR Inhibitor Frequently Overexpressed in Multiple Myeloma Cells and Required for Their Survival
- (2009) Timothy R. Peterson et al. CELL
- An ATP-competitive Mammalian Target of Rapamycin Inhibitor Reveals Rapamycin-resistant Functions of mTORC1
- (2009) Carson C. Thoreen et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- mTOR complex 2 (mTORC2) controls hydrophobic motif phosphorylation and activation of serum- and glucocorticoid-induced protein kinase 1 (SGK1)
- (2008) Juan M. García-Martínez et al. BIOCHEMICAL JOURNAL
- NVP-BEZ235, a Dual PI3K/mTOR Inhibitor, Prevents PI3K Signaling and Inhibits the Growth of Cancer Cells with Activating PI3K Mutations
- (2008) V. Serra et al. CANCER RESEARCH
- Hypoxia regulates TSC1/2 mTOR signaling and tumor suppression through REDD1-mediated 14 3 3 shuttling
- (2008) M. P. DeYoung et al. GENES & DEVELOPMENT
- Targeted polypharmacology: discovery of dual inhibitors of tyrosine and phosphoinositide kinases
- (2008) Beth Apsel et al. Nature Chemical Biology
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now